South Korea · Delayed Price · Currency is KRW CG MedTech Statistics
Total Valuation
CG MedTech has a market cap or net worth of KRW 120.30 billion. The enterprise value is 130.24 billion.
| Market Cap | 120.30B |
| Enterprise Value | 130.24B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CG MedTech has 103.26 million shares outstanding. The number of shares has increased by 13.85% in one year.
| Current Share Class | 103.26M |
| Shares Outstanding | 103.26M |
| Shares Change (YoY) | +13.85% |
| Shares Change (QoQ) | -0.84% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | n/a |
| Float | 61.13M |
Valuation Ratios
The trailing PE ratio is 18.05.
| PE Ratio | 18.05 |
| Forward PE | n/a |
| PS Ratio | 2.35 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 19.87 |
| EV / Sales | 2.54 |
| EV / EBITDA | 26.78 |
| EV / EBIT | 69.43 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.10 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 4.22 |
| Debt / FCF | -0.90 |
| Interest Coverage | 10.64 |
Financial Efficiency
Return on equity (ROE) is 7.09% and return on invested capital (ROIC) is 1.87%.
| Return on Equity (ROE) | 7.09% |
| Return on Assets (ROA) | 0.96% |
| Return on Invested Capital (ROIC) | 1.87% |
| Return on Capital Employed (ROCE) | 1.67% |
| Weighted Average Cost of Capital (WACC) | 3.13% |
| Revenue Per Employee | 426.66M |
| Profits Per Employee | 54.61M |
| Employee Count | 120 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | -3.79B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.44% in the last 52 weeks. The beta is -0.13, so CG MedTech's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | +14.44% |
| 50-Day Moving Average | 1,076.46 |
| 200-Day Moving Average | 1,565.65 |
| Relative Strength Index (RSI) | 55.65 |
| Average Volume (20 Days) | 463,567 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CG MedTech had revenue of KRW 51.20 billion and earned 6.55 billion in profits. Earnings per share was 64.55.
| Revenue | 51.20B |
| Gross Profit | 21.05B |
| Operating Income | 1.88B |
| Pretax Income | 2.75B |
| Net Income | 6.55B |
| EBITDA | 4.86B |
| EBIT | 1.88B |
| Earnings Per Share (EPS) | 64.55 |
Balance Sheet
The company has 10.75 billion in cash and 20.51 billion in debt, with a net cash position of -9.76 billion or -94.51 per share.
| Cash & Cash Equivalents | 10.75B |
| Total Debt | 20.51B |
| Net Cash | -9.76B |
| Net Cash Per Share | -94.51 |
| Equity (Book Value) | 96.02B |
| Book Value Per Share | 946.66 |
| Working Capital | 23.51B |
Cash Flow
In the last 12 months, operating cash flow was -1.91 billion and capital expenditures -20.86 billion, giving a free cash flow of -22.78 billion.
| Operating Cash Flow | -1.91B |
| Capital Expenditures | -20.86B |
| Depreciation & Amortization | 2.99B |
| Net Borrowing | 14.02B |
| Free Cash Flow | -22.78B |
| FCF Per Share | -220.58 |
Margins
Gross margin is 41.11%, with operating and profit margins of 3.66% and 12.80%.
| Gross Margin | 41.11% |
| Operating Margin | 3.66% |
| Pretax Margin | 5.36% |
| Profit Margin | 12.80% |
| EBITDA Margin | 9.50% |
| EBIT Margin | 3.66% |
| FCF Margin | n/a |
Dividends & Yields
CG MedTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.85% |
| Shareholder Yield | -13.85% |
| Earnings Yield | 5.45% |
| FCF Yield | -18.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 5, 2022. It was a forward split with a ratio of 5.
| Last Split Date | Aug 5, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
CG MedTech has an Altman Z-Score of 2.53 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.53 |
| Piotroski F-Score | 2 |